FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657

Leukemia Research

Volumn 34, Issue 10, 2010, Pages 1302-1307

  Goemans, Bianca F ^a   Zwaan, Christian M ^b   Cloos, Jacqueline ^a   de Lange, Desiree ^a   Loonen, Anne H ^a   Reinhardt, Dirk ^c   Hählen, Karel ^b,d   Gibson, Brenda E S ^e   Creutzig, Ursula ^c   Kaspers, Gertjan J L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d DCOG   (Netherlands)

^e UK Childhood Leukaemia Working Party ^*  (United Kingdom)

Author keywords

Acute myeloid leukemia; Childhood leukemia; Drug sensitivity; Flt3; Tyrosine kinase inhibitor

Indexed keywords

CD135 ANTIGEN; GENOMIC DNA; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SU 11657; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CELL STRAIN HL 60; CHILD; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; WILD TYPE;

ADOLESCENT; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; ORGANIC CHEMICALS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 77955980691     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.04.004     Document Type: Article

References (47)

1. Kaspers G.J., Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 2005, 19:2025-2029.
2. Zwaan C.M., Meshinchi S., Radich J.P., et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 2003, 102:2387-2394.
3. Meshinchi S., Woods W.G., Stirewalt D.L., et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001, 97:89-94.
4. Meshinchi S., Alonzo T.A., Stirewalt D.L., et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006, 108:3654-3661.
5. Stirewalt D.L., Kopecky K.J., Meshinchi S., et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 2006, 107:3724-3726.
6. Kusec R., Jaksic O., Ostojic S., et al. More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML). Blood 2006, 108:405-406.
7. Ponziani V., Gianfaldoni G., Mannelli F., et al. The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Leukemia 2006, 20:2074-2076.
8. Kayser S., Schlenk R.F., Londono M.C., et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 2009, 114:2386-2392.
9. Goemans B.F., Zwaan C., Miller M., et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19:1536-1542.
10. Corbacioglu S., Kilic M., Westhoff M.A., et al. Newly identified c-kit receptor tyrosine kinase ITD in childhood AML induces ligand independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 2006, 108:3504-3513.
11. Beghini A., Ripamonti C.B., Cairoli R., et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004, 89:920-925.
12. Boissel N., Leroy H., Brethon B., et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006, 20:965-970.
13. Cairoli R., Beghini A., Grillo G., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006, 107:3463-3468.
14. Paschka P., Marcucci G., Ruppert A.S., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006, 24:3904-3911.
15. Shimada A., Taki T., Tabuchi K., et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006, 107:1806-1809.
16. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
17. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
18. De Angelo D.J., Stone R.M., Heaney M.L., et al. Phase I clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006, 108:3674-3681.
19. Stone R.M., DeAngelo D.J., Klimek V., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005, 105:54-60.
20. Smith B.D., Levis M., Beran M., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103:3669-3676.
21. Zhang W., Konopleva M., Shi Y., et al. Sorafenib (BAY 43-9006) directly targets FLT3-ITD in acute myelogenous leukemia. Blood 2006, 108:255.
22. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
23. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597-3605.
24. Fabian M.A., Biggs W.H., Treiber D.K., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005, 23:329-336.
25. Goodman V.L., Rock E.P., Dagher R., et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007, 13:1367-1373.
26. Fiedler W., Serve H., Dohner H., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005, 105:986-993.
27. Cain J.A., Grisolano J.L., Laird A.D., Tomasson M.H. Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657. Blood 2004, 104:561-564.
28. Sohal J., Phan V.T., Chan P.V., et al. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 2003, 101:3188-3197.
29. Backman U., Christofferson R. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice. Pediatr Res 2005, 57:690-695.
30. Kaspers G.J.L., Veerman A.J.P., Pieters R., et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer 1994, 70:1047-1052.
31. Klumper E., Pieters R., Kaspers G.J.L., et al. In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia 1995, 9:1864-1869.
32. Goemans B.F., Zwaan C.M., Harlow A., et al. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood 2005, 106:3532-3537.
33. Cloos J., Goemans B.F., Hess C.J., et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006, 20:1217-1220.
34. Kiyoi H., Towatari M., Yokota S., et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998, 12:1333-1337.
35. Levis M., Brown P., Smith B.D., et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006, 108:3477-3483.
36. Knapper S., Mills K.I., Gilkes A.F., et al. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3 mutated and wild type cases. Blood 2006, 108:3494-3503.
37. Frohling S., Scholl C., Levine R.L., et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007, 12:501-513.
38. Kim D.W., Jo Y.S., Jung H.S., et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006, 91:4070-4076.
39. de Bont E.S., Fidler V., Meeuwsen T., et al. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002, 8:2856-2861.
40. Hussong J.W., Rodgers G.M., Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000, 95:309-313.
41. Padro T., Ruiz S., Bieker R., et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000, 95:2637-2644.
42. Deininger M. Resistance to imatinib: mechanisms and management. J Natl Compr Cancer Netw 2005, 3:757-768.
43. Heidel F., Solem F.K., Breitenbuecher F., et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006, 107:293-300.
44. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25-35.
45. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
46. Furukawa Y., Vu H.A., Akutsu M., et al. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia 2007, 21:1005-1014.
47. Levis M., Pham R., Smith B.D., Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 2004, 104:1145-1150.